Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on October 14, 2014, regarding events occurring on October 8, 2014. The filing details the entry into a Material Definitive Agreement with Medtronic, Inc. concerning the acquisition of patent rights related to the formulation and pump delivery of natriuretic peptides.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or margin data. The only financial metrics disclosed relate to the specific terms of the Transfer Agreement:
- Upfront Payment: $100,000 payable to Medtronic.
- Maximum Milestone Payments: Up to $7.0 million in aggregate, contingent on achieving defined milestones.
- Royalties: Mid-single-digit royalty on net sales of products.
- Sublicensing: Low double-digit percentage of consideration received from sublicenses.
- Enforcement Awards: Mid-double-digit percentage of monetary awards or settlements from patent enforcement, less costs and attorney fees.
Material Changes
The primary material change is the transfer of intellectual property rights. Medtronic assigned all rights, title, and interest in natriuretic peptide patents and applications previously owned or co-owned by Medtronic to Capricor. Capricor now holds the right to grant licenses and make assignments without Medtronic's approval. This agreement supersedes previous co-ownership arrangements regarding these specific patents, though rights co-owned under a 2011 Clinical Funding Agreement remain with Capricor subject to surviving terms.
Outlook, Risks, and Contingencies
Termination Risks: The agreement includes specific termination clauses that could result in the reassignment of patent rights back to Medtronic:
- Either party may terminate upon 30 days' written notice if a default is not cured within that period.
- Medtronic retains the right to terminate and reclaim rights if Capricor, an affiliate, or a non-party licensee fails to commence a clinical trial of a CD-NP product within 18 months of the effective date.
Confidentiality: Capricor intends to seek confidential treatment for certain terms and provisions of the agreement when filed as an exhibit.
Investor Verification Checklist
- Verify the specific definitions of the "defined milestones" required to trigger the up to $7.0 million in payments.
- Confirm the timeline for the required clinical trial of a CD-NP product to avoid the 18-month termination clause.
- Review the full text of the Transfer Agreement (when filed) to understand the specific patents included in the "Natriuretic Peptide Patents."
- Assess the impact of the mid-single-digit royalty on future gross margins for any commercialized products.